Mechanism of action, clinical research and development, and application prospect of hepatitis B virus core protein allosteric modulators
10.3969/j.issn.1001-5256.2022.08.005
- VernacularTitle:乙型肝炎病毒核心蛋白变构调节剂的作用机理及临床研发和应用前景
- Author:
Hui LIU
1
,
2
;
Fengmin LU
1
;
Jutao GUO
2
Author Information
1. Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China
2. Baruch S. Blumberg Institute, Doylestown, Pennsylvania 18902, USA
- Publication Type:Discussions by Experts
- Keywords:
Hepatitis B Virus;
Core Protein Allosteric Modulators;
Clinical Trial
- From:
Journal of Clinical Hepatology
2022;38(8):1726-1732
- CountryChina
- Language:Chinese
-
Abstract:
Hepatitis B virus (HBV) infection is the main pathogenic factor for chronic hepatitis, and if it is not treated timely and effectively, it may have the risk of developing into end-stage liver diseases such as liver cirrhosis and hepatocellular carcinoma. Neither of the two types of antiviral drugs currently used in clinical practice can completely inhibit viral replication or eliminate viral transcriptional template, which means that covalently closed circular DNA (cccDNA) exists in infected liver cells for a long time, and thus patients with chronic hepatitis B require long-term or even lifelong medication. Therefore, it is of great importance to develop novel anti-HBV drugs. Core protein allosteric modulators (CpAM) are a type of novel anti-HBV drugs and can interfere with HBV nucleocapsid assembly and inhibit the depolymerization of mature nucleocapsid, the formation of cccDNA, and the biogenesis and secretion of HBeAg. CpAM have a great potential in clinical application since they act on various links of viral replication. This article reviews the function of CpAM target protein-core protein, the classification, action targets, and anti-HBV mechanism of CpAM, and the current research status, further development, and application prospect of CpAM.
